Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human Breast Cancer cells: Control vs Treated with Palbociclib

ABSTRACT: Analysis miRNA profiling of breast cancer cells treated without or with palbociclib.Results provide insight into the molecular mechanisms involved in resistance to pabbociclib.

ORGANISM(S): Homo sapiens

PROVIDER: GSE136671 | GEO | 2020/04/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Human Breast Cancer cells: Control vs Treated with Palbociclib

Project description:Human Breast Cancer cells: Control vs Treated with Palbociclib

| PRJNA563027 | ENA

Antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells

2011-01-29 | GSE19777 | GEO

Establishment of palbociclib resistant metastatic breast cancer patient-derived xenograft models

Project description:Identify therapeutic vulnerabilities of palbociclib resistance in metastatic breast cancer patient-derived xenograft models and identify key biomarkers that correlate with development of resistance to inform new treatment directions

2023-07-10 | GSE229235 | GEO

Antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells

Project description:Full title: Expression data from antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells The expression of miR-221/222 were found to be upregulated in fulvestrant resistant breast cancer cells MCF7-FR compared to its drug-sensitive counterpart MCF7. To investigate the role of miR-221/222 in acquired resistance to fulvestrant, we lowered the level of miR-221/222 in MCF7-FR cells using miRNA inhibitors (antagomirs), and compared gene expression profiles before and after treatment. Fulvestrant-resistant breast cancer cells MCF7-FR (originated from drug-sentitive breast cancer model cell line MCF7) were transient-transfected by antigomirs targeting miR221 or miR222 (i.e. si221, si222). All three cell lines, MCF7-FR, siR221, siRNA222 were subjected to gene expression profiling.

2011-01-29 | E-GEOD-19777 | biostudies-arrayexpress

celecoxib-treated vs control breast tumours

Project description:Biopsies and surgical specimens were obtained from breast tumours treated and non-treated with celecoxib 400mg twice daily for 2 weeks

2013-03-28 | E-MTAB-566 | biostudies-arrayexpress

Human breast cancer cells: control vs treated with breast cancer patients' sera

Project description:To investigate the significant differently expressed genes upon the stimulation of breast cancer patients' sera.

2012-08-15 | GSE40108 | GEO

Human breast cancer cells: control vs treated with breast cancer patients' sera

Project description:To investigate the significant differently expressed genes upon the stimulation of breast cancer patients' sera. Cells were untreated or treated with 10% breast cancer patients' sera for 24h followed by isolation of total RNA using TRIZOL. Gene-expression profiling was performed on the CapitalBio 35k human Genome Array microchips (Beijing, China).

| S-ECPF-GEOD-40108 | biostudies-other

O-GlcNAcylation promotes Palbociclib resistance in breast cancer by regulating MITF nuclear translocation

Project description:Cyclin-dependent kinases 4 and 6 (CDK4/6) are essential drivers of the cell cycle and are also critical for the initiation and progression of diverse malignancies. Pharmacological inhibitors targeting CDK4/6 have demonstrated significant activity against various tumor types such as breast cancer. However, resistance to CDK4/6 inhibitors (CDK4/6i) (such as palbociclib) remains an immense obstacle in clinical and the underlying mechanisms have not been fully understood. Using quantitative high-throughput combinational screen (qHTCS) and genomic sequencing, we report that the Microphthalmia-associated transcription factor (MITF), was significantly elevated in palbociclib-resistance cells. Inhibition of MITF can enhance the therapeutic efficacy of Palbociclib and surmount Palbociclib resistance both in vitro and in vivo. Then we found that MITF is interacting with OGT in Palbociclib-resistance cells, and we also identified that Ser49 is the main O-GlcNAc site of MITF. O-GlcNAc of MITF is critical to mediated Palbociclib-resistance in cells.

2024-05-30 | PXD042763 | Pride

Human breast cancer cells: control vs treated with breast cancer patients' sera

2012-08-14 | E-GEOD-40108 | biostudies-arrayexpress

Palbociclib resistance analyses on breast cancer bone metastasis PDX

Project description:Identify mecanisms of metastatic breast cancer resistance to palbociclib by RNAseq analyses.

| EGAS00001006428 | EGA